ABOUT EMISPHERE TECHNOLOGIES, INC.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology; convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. In those cases, use of Emisphere's technology can improve the therapeutic effectiveness of the compounds. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The web site is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding potential third party
collaborations, future performance or financial results, the timing or
potential outcomes of research collaborations or clinical trials, any
market that might develop for any of Emisphere's product candidates and the
sufficiency of Emisphere's cash and other capital resources) are
forward-looking statements that involve risks and uncertainties, including,
but not limited to, the likelihood that one or more potential third party
collaborations may not be consummated, that actual performance or results
could materially differ, that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
|SOURCE Emisphere Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved